Emmaus Life Sciences to Participate in the Cantor Global Healthcare Conference Oct 02, 2018 10:26am EDT
Emmaus, a Leader in Sickle Cell Disease Treatment, Signs Agreement with Cardinal Health to Solidify Distribution Network for Endari™ (L-glutamine oral powder) Sep 19, 2018 9:01am EDT
Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Present at the Seventh Annual Sickle Cell Disease Therapeutics Conference in New York City on September 13th Sep 11, 2018 2:03pm EDT
Emmaus, a Leader in Sickle Cell Disease Treatment, Signs Agreement with McKesson to Expand Distribution Network for Endari™ (L-glutamine oral powder) Aug 27, 2018 8:18am EDT
Emmaus Life Sciences Partners with DMS Pharmaceutical Group to Provide Endari™ (L-glutamine oral powder) to Military Personnel and Beneficiaries for Treatment of Sickle Cell Disease Jul 30, 2018 8:30am EDT
Emmaus Life Sciences Strengthens its Finance & Operations Leadership to Support Commercialization of Endari™ Jul 25, 2018 8:36am EDT
Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease Jul 18, 2018 5:27pm EDT
Emmaus Life Sciences Announces FDA Acceptance of IND Application for Clinical Study of L-glutamine for Treatment of Diverticulosis Jul 09, 2018 8:00am EDT
Sickle Cell Disease Association of America, Inc. Partners With Emmaus Life Sciences, Inc. Jun 19, 2018 8:00am EDT
